trending Market Intelligence /marketintelligence/en/news-insights/trending/qm7OaA5qpGIrh7Zh_x7SrA2 content esgSubNav
In This List

Astellas Pharma's blood cancer drug gets US FDA fast track designation

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

Blog

Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback

Blog

Infographic: The Big Picture 2023 Issuer & Investor Relations Outlook


Astellas Pharma's blood cancer drug gets US FDA fast track designation

The U.S. Food and Drug Administration granted fast-track designation to Astellas Pharma Inc.'s gilteritinib to treat a certain type of blood cancer.

The designation covers the company's study of gilteritinib in adult patients with FLT3+ relapsed or refractory acute myeloid leukemia.

Astellas Pharma said four phase 3 trials of gilteritinib in various AML patient populations are underway.

Gilteritinib is an investigational compound discovered through a research collaboration between Astellas Pharma and Kotobuki Pharmaceutical Co. Ltd.

Astellas has exclusive global rights to the drug.